Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025
June 26th, 2025 2:17 PM
By: Newsworthy Staff
Annovis Bio Inc. will present its latest Alzheimer’s disease research findings at the Alzheimer’s Association International Conference in 2025, highlighting progress in its clinical program and pharmacokinetic data for buntanetap.
Annovis Bio Inc. (NYSE: ANVS), a company specializing in neurodegenerative disease therapies, is set to participate in the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The event will feature four scientific posters from Annovis, detailing advancements in its Alzheimer’s clinical program and pharmacokinetic research on buntanetap, its leading drug candidate. The presentations will cover a Phase III trial design, efficacy and safety outcomes, and comparative pharmacokinetics across different drug formulations in both animal and human studies. This participation underscores the company’s commitment to developing treatments that target neurotoxic proteins, aiming to enhance brain function and patient quality of life. For further details, visit https://ibn.fm/w0fFP.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
